| Wall Street Analysts Believe Arcturus Therapeutics (ARCT) Could Rally 503.6%: Here's is How to Trade |
The consensus price target hints at a 503.6% upside potential for Arcturus Therapeutics (ARCT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2025-05-15 15:00:45 |
Czytaj oryginał (ang.) |
| Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2025 Earnings Call Transcript |
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Neda Safarzadeh - Vice President, Head of Investor Relations, Public Relations and Marketing Joe Payne - President and Chief Executive Officer Andy Sassine - Chief Financial Officer Pad Chivukula - Chief Scientific Officer and Chief Operating Officer Conference Call Participants Lili Nsongo - Leerink Partners Yasmeen Rahimi - Piper Sandler Evan Wang - Guggenheim Securities Jake Roberge - William Blair Whitney Ijem - Canaccord Genuity Samantha Schaeffer - Cantor Fitzgerald Tom Shrader - BTIG Yigal Nochomovitz - Citi Yanan Zhu - Wells Fargo Yale Jen - Laidlaw & Company Operator Good day. I would like to welcome everyone to Arcturus Therapeutics' First Quarter 2025 Earnings Call. |
seekingalpha.com |
2025-05-12 23:40:37 |
Czytaj oryginał (ang.) |
| Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates |
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $1.58. This compares to loss of $1 per share a year ago. |
zacks.com |
2025-05-12 22:10:48 |
Czytaj oryginał (ang.) |
| Earnings Preview: Arcturus Therapeutics (ARCT) Q1 Earnings Expected to Decline |
Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-05-05 15:05:53 |
Czytaj oryginał (ang.) |
| Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025 |
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended March 31, 2025 after the market close on Monday, May 12 and will also host a conference call and webcast at 4:30 pm Eastern Time on May 12, 2025. |
businesswire.com |
2025-04-22 20:01:00 |
Czytaj oryginał (ang.) |
| Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate |
The FDA bestows a Fast Track designation to ARCT's sa-mRNA vaccine candidate, ARCT-2304, for active immunization to prevent pandemic influenza A virus H5N1. |
zacks.com |
2025-04-11 16:50:40 |
Czytaj oryginał (ang.) |
| Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2024 Earnings Call Transcript |
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q4 2024 Earnings Conference Call March 6, 2025 4:30 PM ET Company Participants Neda Safarzadeh - Vice President, Head of Investor Relations Joe Payne - President and Chief Executive Officer, Director of the Board Andy Sassine - Chief Financial Officer Pad Chivukula - Chief Scientific Officer and Chief Operating Officer Conference Call Participants Lili Nsongo - Leerink Yasmeen Rahimi - Piper Sandler Evan Wang - Guggenheim Securities Myles Minter - William Blair Joohwan Kim - Canaccord Genuity Pete Stavropoulos - Cantor Tom Shrader - BTIG Thomas Yip - HCW Yanan Zhu - Wells Fargo Yale Jen - Laidlaw & Company Operator Good day, everyone, and welcome to today's Arcturus Therapeutics Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2025-03-06 23:44:04 |
Czytaj oryginał (ang.) |
| Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates |
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $1.11 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.32 per share a year ago. |
zacks.com |
2025-03-06 20:15:30 |
Czytaj oryginał (ang.) |
| Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress |
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the fourth quarter ended December 31, 2024, and provided corporate updates. “We continue to progress our flagship rare disease programs and look forward to sharing meaningful Phase 2 in. |
businesswire.com |
2025-03-06 18:01:00 |
Czytaj oryginał (ang.) |
| Arcturus Therapeutics to Present at Leerink's Global Healthcare Conference 2025 |
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate at a fireside chat hosted by Leerink's Global Healthcare Conference 2025 in Miami, on Wednesday, March 12, 2025, at 10:40 a.m. Eastern Time. Webcast link can be found under Inve. |
businesswire.com |
2025-03-05 18:30:00 |
Czytaj oryginał (ang.) |
| Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025 |
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter and year ended December 31, 2024 after the market close on Thursday, March 6 and will also host a conference call and webcast at 4:30 p.m. Eastern Time. |
businesswire.com |
2025-02-24 18:01:00 |
Czytaj oryginał (ang.) |
| European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine |
- KOSTAIVE represents a significant advancement in vaccine technology, demonstrating superior immunogenicity and antibody persistence for up to 12 months post-vaccination compared to conventional mRNA COVID-19 vaccines in clinical trials WALTHAM, Mass. and SAN DIEGO , Feb. 14, 2025 /PRNewswire/ -- Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (Nasdaq: ARCT) today announced that the European Commission has granted marketing authorization for KOSTAIVE ® (ARCT-154), a self-amplifying mRNA COVID-19 vaccine, for individuals 18 years and older. |
prnewswire.com |
2025-02-14 10:30:00 |
Czytaj oryginał (ang.) |
| European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine |
WALTHAM, Mass. & SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (Nasdaq: ARCT) today announced that the European Commission has granted marketing authorization for KOSTAIVE® (ARCT-154), a self-amplifying mRNA COVID-19 vaccine, for individuals 18 years and older. KOSTAIVE is the first sa-mRNA COVID-19 vaccine to receive approval from the European Commission (EC). KOSTAIVE is currently marketed in Japan against COVID-. |
businesswire.com |
2025-02-14 10:00:00 |
Czytaj oryginał (ang.) |
| Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19 |
TOKYO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi) announced today that it has received approval for a partial amendment to the manufacturing and marketing approval of “KOSTAIVE® for Intramuscular Injection,” a self-amplifying mRNA vaccine for protection against COVID-19, to include domestic manufacturing sites in Japan. Meiji Seika Pharma and ARCALIS Co., Ltd. (Headquarters: Minami-soma City, Fukushima. |
businesswire.com |
2025-01-31 05:00:00 |
Czytaj oryginał (ang.) |
| Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference |
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate at a fireside chat hosted by Guggenheim Securities SMID Cap Biotech Conference in New York, on Thursday, February 6, 2025, at 10:30 a.m. Eastern Time. Webcast link can be found. |
businesswire.com |
2025-01-30 18:01:00 |
Czytaj oryginał (ang.) |
| Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency |
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the first CF and OTC deficiency participants initiated dosing in December 2024, in the Company's Phase 2 multiple ascending dose studies. Each participant in the Phase 2 CF study (NCT06747858) is expected t. |
businesswire.com |
2025-01-06 18:01:00 |
Czytaj oryginał (ang.) |
| Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that Joseph Payne, President & Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, on Wednesday, January 15, 2025, at 9:45 a.m. Pacific Time. A webcas. |
businesswire.com |
2024-12-16 18:01:00 |
Czytaj oryginał (ang.) |
| Arcturus Therapeutics to Attend Upcoming Investor Conferences |
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences: Piper Sandler 36th Annual Healthcare Conference (Fireside Chat) Tuesday, December 3, 2024 (4:30 p.m. ET) Citi's 2024 Global Healthcare Con. |
businesswire.com |
2024-11-26 18:01:00 |
Czytaj oryginał (ang.) |
| Arcturus Therapeutics to Present at Jefferies London Healthcare Conference |
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will present at Jefferies London Healthcare Conference in London, on Wednesday, November 20, 2024, at 9:30 am GMT. A webcast and replay of the presentation will be available on the Investor Rela. |
businesswire.com |
2024-11-18 22:00:00 |
Czytaj oryginał (ang.) |
| Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data |
Interim results from phase 2 proof-of-concept study, using LUNAR-CF for treatment of patients with Cystic Fibrosis, expected 1st half of 2025. The global Cystic Fibrosis market size is projected to reach $62.57 billion by 2032. Interim results from phase 2 proof-of-concept study, using LUNAR-OTC for treatment of patients with OTC Deficiency, expected 1st half of 2025. |
seekingalpha.com |
2024-11-14 15:44:02 |
Czytaj oryginał (ang.) |
| Meiji Seika Pharma Announces Investment in ARCALIS, Inc. |
TOKYO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi; hereinafter referred to as "Meiji Seika Pharma") today announced its investment in ARCALIS, Inc. (Headquarters: Minami-soma City, Fukushima Prefecture; President: Satoshi Takamatsu; hereinafter referred to as "ARCALIS"). ARCALIS is a joint venture between Axcelead, Inc., which manages a group of world-class pharmaceutical and healthcare platform companie. |
businesswire.com |
2024-11-14 03:00:00 |
Czytaj oryginał (ang.) |
| Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial |
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a “Study Can Proceed” notification for the Company's Investigational New Drug (IND) application, ARCT-2304, a self-amplifying mRNA (sa-mRNA) vaccine ca. |
businesswire.com |
2024-11-11 18:01:00 |
Czytaj oryginał (ang.) |
| Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2024 Earnings Call Transcript |
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Neda Safarzadeh - Vice President, Head of Investor Relations Joseph Payne - President and CEO Andrew Sassine - CFO Pad Chivukula - CSO & COO Conference Call Participants Lili Nsongo - Leerink Whitney Ijem - Canaccord Genuity Evan Wang - Guggenheim Securities Myles Minter - William Blair Samantha Schaeffer - Cantor Fitzgerald Yale Jen - Laidlaw & Company Yigal Nochomovitz - Citi Operator Good day, everyone, and welcome to today's Arcturus Therapeutics Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2024-11-08 01:24:48 |
Czytaj oryginał (ang.) |
| Arcturus Therapeutics (ARCT) Reports Q3 Loss, Lags Revenue Estimates |
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $0.61 per share a year ago. |
zacks.com |
2024-11-07 20:57:37 |
Czytaj oryginał (ang.) |
| Arcturus Gears Up to Report Q3 Earnings: Here's What to Expect |
On ARCT's third-quarter 2024 earnings call, investors' focus is likely to be on the upcoming launch of its COVID-19 vaccine, Kostaive and other pipeline updates. |
zacks.com |
2024-11-04 13:05:14 |
Czytaj oryginał (ang.) |
| Arcturus Therapeutics (ARCT) Upgraded to Buy: What Does It Mean for the Stock? |
Arcturus Therapeutics (ARCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-10-30 15:01:14 |
Czytaj oryginał (ang.) |
| ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty |
Arcturus stock gains as the company reports that its sa-mRNA COVID-19 vaccine, ARCT-154, shows superior efficacy compared with treatment with Comirnaty. |
zacks.com |
2024-10-01 15:51:11 |
Czytaj oryginał (ang.) |
| Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination |
Head-to-head data, presented at OPTIONS XII for the Control of Influenza Conference, demonstrates advantage of sa-mRNA over conventional mRNA in duration of immune response; Results highlight CSL and Arcturus Therapeutics' commitment to advancing COVID-19 vaccine innovation to protect public health. WALTHAM, Mass. |
prnewswire.com |
2024-09-30 12:00:00 |
Czytaj oryginał (ang.) |
| Here's Why Investors Should Invest in Arcturus Stock Now |
Here, we are discussing some reasons why investing in ARCT stock now may turn out to be a prudent move. |
zacks.com |
2024-09-16 16:31:07 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for September 13th |
ARCT, MHO, FMBH, PAM and ANGO have been added to the Zacks Rank #1 (Strong Buy) List on September 13, 2024. |
zacks.com |
2024-09-13 12:16:07 |
Czytaj oryginał (ang.) |
| Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma |
Approval underscores CSL and Arcturus Therapeutics' commitment to delivering disruptive technologies to combat COVID-19 and other respiratory viral diseases to protect public health KOSTAIVE®, the world's first self-amplifying mRNA (sa-mRNA) COVID-19 vaccine, was approved for adults 18 years of age and older in November 2023 The updated sa-mRNA COVID-19 vaccine is tailored to protect against the JN.1 lineage of Omicron subvariants Meiji Seika Pharma, CSL's exclusive partner in Japan, will begin vaccine distribution in time for the October COVID-19 vaccination campaign CSL and Arcturus Therapeutics' partnership delivers on the promise to advance innovative vaccine technology for viral respiratory diseases KING OF PRUSSIA, Pa. and SAN DIEGO , Sept. |
prnewswire.com |
2024-09-13 12:15:00 |
Czytaj oryginał (ang.) |
| Does Arcturus Therapeutics (ARCT) Have the Potential to Rally 216.35% as Wall Street Analysts Expect? |
The average of price targets set by Wall Street analysts indicates a potential upside of 216.4% in Arcturus Therapeutics (ARCT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-09-02 14:55:41 |
Czytaj oryginał (ang.) |
| What Makes Arcturus Therapeutics (ARCT) a New Strong Buy Stock |
Arcturus Therapeutics (ARCT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-08-23 17:01:42 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for August 23rd |
RHHBY, SBSI, FCCO, APELY and ARCT have been added to the Zacks Rank #1 (Strong Buy) List on August 23, 2024. |
zacks.com |
2024-08-23 12:20:30 |
Czytaj oryginał (ang.) |
| High-Risk, High-Reward: Arcturus Nears Commercialization Of Kostaive Vaccine |
Arcturus is close to launching the Kostaive COVID-19 vaccine in Japan, with ongoing work on variant protection and influenza vaccine. The company has been able to consistently derive research revenues, maintaining liquidity and avoiding debt, with potential for significant revenue from vaccine orders. Valuation suggests Arcturus may be undervalued compared to peers, with a revised model showing potential for significant revenue growth by 2026. |
seekingalpha.com |
2024-08-09 09:27:05 |
Czytaj oryginał (ang.) |
| Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2024 Earnings Call Transcript |
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q2 2024 Earnings Call Transcript August 5, 2024 4:30 PM ET Company Participants Neda Safarzadeh - VP, Head of IR, Public Relations and Marketing Joe Payne - President and CEO Andy Sassine - CFO Conference Call Participants Joohwan Kim - Canaccord Genuity Yasmeen Rahimi - Piper Sandler Evan Wang - Guggenheim Securities Myles Minter - William Blair Yanan Zhu - Wells Fargo Yigal Nochomovitz - Citigroup Samantha Schaeffer - Cantor Fitzgerald Ed Arce - H.C. Wainwright Yale Jen - Laidlaw & Company Operator Greetings and welcome to Arcturus Therapeutics' Second Quarter 2024 Earnings Call. |
seekingalpha.com |
2024-08-06 00:50:28 |
Czytaj oryginał (ang.) |